ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag art vaccine innovation neuroscience

a mockup of an at-home COVID-19 test in development
Top Technical Advances of 2020
Shawna Williams | Dec 18, 2020 | 3 min read
The pandemic spurred innovation in a variety of ways, from CRISPR-based diagnostics to cell biology benchwork at home.
Top 10 Innovations 2021
2021 Top 10 Innovations
The Scientist | Dec 1, 2021 | 10+ min read
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
2020 Top 10 Innovations
The Scientist | Dec 1, 2020 | 10+ min read
From a rapid molecular test for COVID-19 to tools that can characterize the antibodies produced in the plasma of patients recovering from the disease, this year’s winners reflect the research community’s shared focus in a challenging year.
Human Clinical Trials Begin For Cervical Cancer Vaccines
Steve Bunk | Oct 26, 1997 | 6 min read
Efforts are under way to develop a vaccine against one of the world's deadliest illnesses, cervical cancer. Along with a number of university research laboratories, at least a half-dozen biotechnology and pharmaceutical companies are beginning clinical trials or are in preclinical development of such drugs. Efficacy in humans remains to be firmly established, but if the vaccines progress to later-phase trials, challenging jobs for immunologists, microbiologists, and biochemists will multiply. "
Genome Investigator Craig Venter Reflects On Turbulent Past And Future Ambitions
Karen Young Kreeger | Jul 23, 1995 | 8 min read
And Future Ambitions Editor's Note: For the past four years, former National Institutes of Health researcher J. Craig Venter has been a major figure in the turbulent debates and scientific discoveries surrounding the study of genes and genomes. Events heated up in 1991, when NIH attempted to patent gene fragments, which were isolated using Venter's expressed sequence tag (EST)/complementary DNA (cDNA) approach for discovering human genes (M.A. Adams et al., Science, 252:1651-6, 1991). NIH's mo
Those We Lost in 2018
Ashley Yeager | Dec 26, 2018 | 10+ min read
The scientific community said goodbye to a number of leading researchers this year.
The Four R's
Amy Norton | Nov 21, 2004 | 7 min read
Teams at each of New York City's leading universities are making important research advances.
New NIH Procedures To Shield Clinicians From Grants Bias
Bruce Agnew | May 10, 1998 | 7 min read
As Mark Twain may--or, according to some sources, may not--have said about the weather, everybody has grumbled for years that National Institutes of Health peer-review study sections are stacked against clinical research, but nobody ever does anything about it. Now, that's changing, along with a lot of other standard operating procedures in NIH's peer-review system. NIH's Center for Scientific Review (CSR), which runs the panels that review about 70 percent of NIH grant applications, is about
Squeeze More from Your Samples
Aileen Constans(aconstans@the-scientist.com) | Mar 27, 2005 | 6 min read
In the mid-1990s, toxicologist Raymond Biagini was looking for a faster way to evaluate pest-control workers for exposure to pesticides.
Mail
The Scientist Staff | Dec 1, 2007 | 6 min read
To frame, or not to frame? Re: "The future of public engagement,"1 the first thing scientists need to do is abandon all talk of tentativeness, paradigms, and social construct when talking to the public about science. This model of science is appropriate in certain circles, but I see not a shred of evidence that it has improved public scientific literacy, and [I see] a great deal of evidence that it has been used by charlatans to dismiss scientific findings or push bogus alternativ

Run a Search

ADVERTISEMENT